ABAC THERAPEUTICS
ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of MDR Gram-negative infections. While potent pathogen-specific antibacterial activity is essential, we believe that it is necessary to incorporate early other pharmaceutical properties, such as suitable pharmacokinetics and toxicological characteristics, to maximize the chance of success in clinical development.
ABAC THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Therapeutics
Founded:
2014-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.abactherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
(+34) 93 230 11 54
Total Funding:
16 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Grupo Ferrer Internacional
Grupo Ferrer Internacional investment in Series A - ABAC Therapeutics
Global health sciences venture fund
Global health sciences venture fund investment in Series A - ABAC Therapeutics
Pontifax
Pontifax investment in Series A - ABAC Therapeutics
Caixa Capital Risc
Caixa Capital Risc investment in Series A - ABAC Therapeutics
Debiopharm Innovation Fund
Debiopharm Innovation Fund investment in Series A - ABAC Therapeutics
Official Site Inspections
http://www.abactherapeutics.com Semrush global rank: 6.15 M Semrush visits lastest month: 1.31 K
Unable to get host informations!!!
More informations about "ABAC Therapeutics"
ABAC Therapeutics - Crunchbase Company Profile & Funding
ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of MDR Gram-negative infections. While potent pathogen-specific antibacterial activity is essential, we โฆSee details»
ABAC Therapeutics SL - Drug pipelines, Patents, Clinical trials
Www.abactherapeutics.com. Startups | Subsidiary Company | 2014 | Spain | 10-50 | www.abactherapeutics.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational โฆSee details»
ABAC Therapeutics Company Profile 2024: Valuation, Investors ...
Information on acquisition, funding, cap tables, investors, and executives for ABAC Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
ABAC Therapeutics - LinkedIn
ABAC Therapeutics is committed to finding therapeutic solutions for patients that are infected with highly antibiotic-resistant bacterial pathogens and that leave affected patients with few (or no ...See details»
ABAC Therapeutics Inc - Company Profile and News
Company profile page for ABAC Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
ABAC Therapeutics Company Profile - Office Locations ... - Craft
ABAC Therapeutics has 5 employees at their 1 location and $19.97 m in total funding,. See insights on ABAC Therapeutics including office locations, competitors, revenue, financials, โฆSee details»
ABAC Therapeutics: Contact Details and Business Profile
Abactherapeutics.com; View Similar People. Related Companies BioTech Foods. 54 $600k B-wom. 8 $7m Cross Road Biotech. 4 $5m Laconicum. 11 $5m Neuropharma. 24 Oncomatryx โฆSee details»
ABAC Therapeutics - Company Profile - Tracxn
Sep 27, 2024 ABAC Therapeutics - Early stage biopharma developing precision drugs for MDR bacterial infections. Acquired by TIBIDABO VENTURES. Raised a total funding of $19.8M โฆSee details»
Abac Therapeutics - Overview, News & Similar companies
Who is Abac Therapeutics. ABAC Therapeutics is committed to finding therapeutic solutions for patients that are infected with highly antibiotic-resistant bacterial pathogens and that leave โฆSee details»
Abactherapeutics - CoBee Company Profile & Funding Rounds
Abactherapeutics. ABAC develops antimicrobial agents for the treatment of bacterial infections. Business Model: Revenue: $5M. Employees: 11-50. Rankings # 974 in Life Science Industries โฆSee details»
ABAC Therapeutics - VentureRadar
Similar Companies: Sun BioPharma USA Privately Held Sun BioPharma is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators, and โฆSee details»
ABAC Therapeutics - Products, Competitors, Financials, Employees ...
Scientists from Spain and India lead an international project to develop new antibiotics against Gram-negative bacteria. Sep 9, 2022. Text Size: A+ Bengaluru (Karnataka) [India], September โฆSee details»
Abac Therapeutics - Overview, CEO, Products, Business - Easyleadz
Abac Therapeutics is a private company and Abac Therapeutics is classified as a Non Government company. Abac Therapeutics is a Biotechnology based company and has โฆSee details»
ABAC Therapeutics Announces โฌ16 Million Series A to develop โฆ
Feb 15, 2018 Proceeds to support development of multiple novel first-in-class antibiotics . BARCELONA, Spain โ February 15th, 2018 โ ABAC Therapeutics (ABAC), a leader in โฆSee details»
ABAC Therapeutics raises 16 million euros from investors including ...
Feb 15, 2018 Spain-based ABAC Therapeutics, a leader in pathogen-specific antibiotics, announced today the closing of a 16 million euros (~$20 million) Series A round.See details»
ABAC Therapeutics SL (ABAC Therapeutics SL) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธด โฆ
ๆบๆ ง่ฝๆฐ่ฏๆ ๆฅๅบๆฏๆบๆ ง่ฝไธไธบ็ๅฝ็งๅญฆไบบๅฃซๆๅปบ็ๅบไบai็ๅๆฐ่ฏๆ ๆฅๅนณๅฐ๏ผๅฉๆจๅ จๆนไฝๆๅๆจ็็ ๅไธๅณ็ญๆ็ใSee details»
ABAC Therapeutics Announces โฌ16 Million Series A to ... - Newswire
Feb 15, 2018 ABAC's lead program targets multi-drug resistant Acinetobacter baumannii, an increasingly fatal pathogen recently nominated by the World Health Organization as the most โฆSee details»
ABAC Therapeutics Announces โฌ16M Series A to Develop
Feb 15, 2018 MADRID and BARCELONA, Spain, February 15, 2018 /PRNewswire/ --ABAC Therapeutics (ABAC), a leader in pathogen-specific antibiotics, announced today the closing โฆSee details»
ABAC Therapeutics Announces โฌ16 Million Series A to Develop โฆ
Proceeds to support development of multiple novel first-in-class antibiotics. MADRID and BARCELONA, Spain, February 15, 2018 /PRNewswire/ โ ABAC Therapeutics (ABAC), a โฆSee details»
ABAC Therapeutics Announces โฌ16 Million Series A to Develop โฆ
Feb 15, 2018 ABAC's lead program targets multi-drug resistant Acinetobacter baumannii, an increasingly fatal pathogen recently nominated by the World Health Organization as the most โฆSee details»